Our funders

NC3Rs funders 

In financial year 2024/25 the NC3Rs had a budget of £16.54M. We receive core funding from the MRC and BBSRC, which are part of UK Research and Innovation (UKRI). Core funding is reviewed every five years. In financial year 2024/25 the core funding allocation was £10.10M. In addition to this, we received funding for specific programmes and posts and co-funding for grants from other research funders. This included funding from the following organisations:

• Association of the British Pharmaceutical Industry (ABPI)*
• Bill and Melinda Gates Foundation
• British Heart Foundation
• Cancer Research UK
• Corteva Agriscience
• Department for Science, Innovation and Technology (DSIT)
• Engineering and Physical Sciences Research Council
• GSK
• Shell
• Syngenta
• The European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC)
• Unilever
• Wellcome

* In accordance with the ABPI's Code of Practice regulating the pharmaceutical industry, the following companies have provided funding to the NC3Rs as part of the ABPI-NC3Rs collaboration: AstraZeneca, Covance Laboratories, Charles River Laboratories and UCB Pharma. 

Budget 

Table 1 illustrates the NC3Rs income and expenditure for the financial year 2024/25. Expenditure is divided across three areas – research and innovation awards made to universities and SMEs, support for early career researchers (e.g. funding for PhD studentships) and a diverse range of programmes of work led by NC3Rs scientific staff. There was an underspend of £220k at financial year end primarily due to unavoidable delays in some awards and contracts starting.

Table 1: Income and expenditure